Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb

BACKGROUND: In 2016, the FDA approved infliximab-dyyb (IFX-dyyb) as a biosimilar to infliximab (IFX). Deemed to have comparable efficacy and safety to IFX, IFX-dyyb is 20%-30% less expensive, allowing significant cost savings for institutions and some payers. In 2018, IFX was reported to be the drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhat, Shubha, Altajar, Sarah, Shankar, Divya, Zahorian, Toni, Robert, Regine, Qazi, Taha, Shah, Bhavesh, Farraye, Francis A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390955/
https://www.ncbi.nlm.nih.gov/pubmed/32223602
http://dx.doi.org/10.18553/jmcp.2020.26.4.410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390955/
https://www.ncbi.nlm.nih.gov/pubmed/32223602
http://dx.doi.org/10.18553/jmcp.2020.26.4.410

Ejemplares similares